Loading...
Header Logo
Keywords
Last Name
Institution

COLIN P DINNEY

TitleProfessor
InstitutionMD Anderson
DepartmentUrology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Duplisea JJ, Dinney CPN. Should chemotherapy still be used to treat all muscle invasive bladder cancer in the "era of immunotherapy"? Expert Rev Anticancer Ther. 2019 Jul; 19(7):543-545. PMID: 31164019.
      View in: PubMed
    2. Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, Zhang S, Wang Z, Lee JG, Lee S, Cogdell D, Zhang M, Wei P, Grossman HB, Kamat A, Duplisea JJ, Ferguson JE, Huang H, Dadhania V, Gao J, Dinney C, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 May 07; 27(6):1781-1793.e4. PMID: 31067463.
      View in: PubMed
    3. Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Mar 12. PMID: 30864005.
      View in: PubMed
    4. Narayan VM, Lim AH, Dinney CPN. Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. Eur Urol. 2019 Jun; 75(6):1034-1035. PMID: 30833138.
      View in: PubMed
    5. Plote D, Choi W, Mokkapati S, Sundi D, Ferguson JE, Duplisea J, Parker NR, Yla-Herttuala S, Committee SCB, McConkey D, Schluns KS, Dinney CP. Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncoimmunology. 2019; 8(5):e1577125. PMID: 31069136.
      View in: PubMed
    6. Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 Feb 19; 26(8):2241-2256.e4. PMID: 30784602.
      View in: PubMed
    7. Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 Jun; 37(6):354.e19-354.e26. PMID: 30777393.
      View in: PubMed
    8. Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, Parker NR, Dinney CP. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol. 2018 Nov 11. PMID: 30415317.
      View in: PubMed
    9. Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2019 01; 75(1):8-10. PMID: 30301695.
      View in: PubMed
    10. Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D. Overall survival in older patients with cancer. BMJ Support Palliat Care. 2018 Sep 22. PMID: 30244203.
      View in: PubMed
    11. Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 May; 2(3):286-293. PMID: 31200843.
      View in: PubMed
    12. Farnum JA, Vikram R, Rao A, Bedi D, Dinney CP, Matin SF. Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. J Endourol. 2018 09 12; 32(9):806-811. PMID: 30014707.
      View in: PubMed
    13. Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World J Urol. 2019 Jan; 37(1):51-60. PMID: 30109483.
      View in: PubMed
    14. Duplisea JJ, Mason RJ, Reichard CA, Li R, Shen Y, Boorjian SA, Dinney CP. Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can Urol Assoc J. 2019 Feb; 13(2):24-28. PMID: 30138098.
      View in: PubMed
    15. Kukreja JB, Metcalfe MJ, Qiao W, Kamat AM, Dinney CPN, Navai N. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus. 2018 Jul 19. PMID: 30033071.
      View in: PubMed
    16. van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli M, Geavlete B, Moldoveanud C, Ene C, Dinney CP, Czerniak B, Schalken JA, Kiemeney LALM, Ribal MJ, Witjes JA, Alcaraz A. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenetics. 2018; 10:71. PMID: 29854012.
      View in: PubMed
    17. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034. PMID: 29804202.
      View in: PubMed
    18. Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65. PMID: 29763719.
      View in: PubMed
    19. Mmeje CO, Benson CR, Nogueras-González GM, Jayaratna IS, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Navai N, Shah JB. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int. 2018 07; 122(1):89-98. PMID: 29569824.
      View in: PubMed
    20. Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP, Navai N, Shah JB, Wang XS. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov. 2018 Jun; 25(3):242-250. PMID: 29557251.
      View in: PubMed
    21. Lian J, Lin SH, Ye Y, Chang DW, Huang M, Dinney CP, Wu X. Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer. Oncotarget. 2018 Mar 13; 9(19):14895-14908. PMID: 29599914.
      View in: PubMed
    22. Zhang S, Wang Y, Bondaruk J, Majewski T, Yao H, Lee S, Lee JG, Cogdell D, Lotan Y, Dinney C, Wei P, Baggerly K, Czerniak B. Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus. 2019 Jul; 5(4):664-675. PMID: 29428551.
      View in: PubMed
    23. Tu H, Dinney CP, Ye Y, Grossman HB, Lerner SP, Wu X. Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr. 2018 02 01; 107(2):208-216. PMID: 29529165.
      View in: PubMed
    24. Tu H, Wen CP, Tsai SP, Chow WH, Wen C, Ye Y, Zhao H, Tsai MK, Huang M, Dinney CP, Tsao CK, Wu X. Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ. 2018 01 31; 360:k134. PMID: 29386192.
      View in: PubMed
    25. Westhoff E, Wu X, Kiemeney LA, Lerner SP, Ye Y, Huang M, Dinney CP, Vrieling A, Tu H. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer. 2018 05 01; 142(9):1797-1804. PMID: 29235103.
      View in: PubMed
    26. Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. 2018 May; 26(5):1561-1568. PMID: 29197959.
      View in: PubMed
    27. Williams SB, Kamat AM, Mmeje C, Ye Y, Huang M, Chang DW, Dinney CP, Wu X. Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. Oncotarget. 2017 Oct 24; 8(51):88782-88791. PMID: 29179475.
      View in: PubMed
    28. Li R, Metcalfe MJ, Ferguson JE, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 02; 121(2):244-251. PMID: 28872778.
      View in: PubMed
    29. Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ. Risk factors for falls in older patients with cancer. BMJ Support Palliat Care. 2018 Mar; 8(1):34-37. PMID: 28860112.
      View in: PubMed
    30. Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ. Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. J Geriatr Oncol. 2018 01; 9(1):81-83. PMID: 28844850.
      View in: PubMed
    31. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416. PMID: 28834453.
      View in: PubMed
    32. Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol. 2017 09; 67:126-133. PMID: 28823575.
      View in: PubMed
    33. Li R, Sylvester R, Dinney CP, Kamat AM. Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer. 2017 Jul 27; 3(3):147-148. PMID: 28824941.
      View in: PubMed
    34. Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ. Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer. 2017 Jul 27; 3(3):145-146. PMID: 28824940.
      View in: PubMed
    35. Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953. PMID: 28731777.
      View in: PubMed
    36. Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583. PMID: 28753816.
      View in: PubMed
    37. Zargar H, Shah JB, van de Putte EEF, Potvin KR, Zargar-Shoshtari K, van Rhijn BW, Daneshmand S, Holzbeierlein JM, Spiess PE, Winquist E, Horenblas S, Dinney C, Black PC, Kassouf W. Dose dense MVAC prior to radical cystectomy: a real-world experience. World J Urol. 2017 Nov; 35(11):1729-1736. PMID: 28625005.
      View in: PubMed
    38. Myers AL, Zhang YP, Kawedia JD, Zhou X, Sobocinski SM, Metcalfe MJ, Kramer MA, Dinney CPN, Kamat AM. Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs R D. 2017 Jun; 17(2):297-304. PMID: 28470465.
      View in: PubMed
    39. Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget. 2017 May 23; 8(21):34205-34222. PMID: 27494900.
      View in: PubMed
    40. Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, Dinney CP, Czerniak B, Guo CC. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506. PMID: 28371875.
      View in: PubMed
    41. Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, Lee S, Lee JG, Fuentes-Mattei E, Willis D, Zhang L, Guo CC, Yao H, Baggerly K, Lotan Y, Lerner SP, Dinney C, McConkey D, Bar-Eli M, Czerniak B. Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017 01 19; 7:40714. PMID: 28102366.
      View in: PubMed
    42. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 09; 4(5):720-724. PMID: 28753837.
      View in: PubMed
    43. Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB. Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery. 2017 05; 161(5):1246-1254. PMID: 28081955.
      View in: PubMed
    44. Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat A. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology. 2017; 6(2):e1265719. PMID: 28344874.
      View in: PubMed
    45. Shore ND, Dinney C, Uzzo R. The society of urologic oncology clinical trials consortium: A brief history and overview. Rev Urol. 2017; 19(2):122-124. PMID: 28959150.
      View in: PubMed
    46. Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C, McConkey DJ. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget. 2016 Dec 06; 7(49):80164-80174. PMID: 27845906.
      View in: PubMed
    47. Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691. PMID: 27753185.
      View in: PubMed
    48. McConkey DJ, Choi W, Ochoa A, Dinney CPN. Intrinsic subtypes and bladder cancer metastasis. Asian J Urol. 2016 Oct; 3(4):260-267. PMID: 29264194.
      View in: PubMed
    49. Biebighauser KC, Gao J, Rao P, Landon G, Pagliaro L, Dinney CPN, Karam J, Navai N. Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. Asian J Urol. 2017 Apr; 4(2):124-127. PMID: 29264217.
      View in: PubMed
    50. Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016 Oct; 12:105-117. PMID: 27612592.
      View in: PubMed
    51. Oshiro H, Czerniak BA, Sakamaki K, Tsuta K, Bondaruk J, Keyhani A, Dinney CP, Nagai T, Kamat AM. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. Medicine (Baltimore). 2016 Aug; 95(31):e4500. PMID: 27495099.
      View in: PubMed
    52. Navai N, Benedict WF, Zhang G, Abraham A, Ainslie N, Shah JB, Grossman HB, Kamat AM, Dinney CP. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon a2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol. 2016 11; 23(12):4110-4114. PMID: 27387678.
      View in: PubMed
    53. Chen M, Rothman N, Ye Y, Gu J, Scheet PA, Huang M, Chang DW, Dinney CP, Silverman DT, Figueroa JD, Chanock SJ, Wu X. Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. Genes Cancer. 2016 Jul; 7(7-8):229-239. PMID: 27738493.
      View in: PubMed
    54. Chedgy EC, Douglas J, Wright JL, Seiler R, van Rhijn BW, Boormans J, Todenhöfer T, Dinney CP, Collins CC, Van der Heijden MS, Black PC. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urol Oncol. 2016 10; 34(10):469-76. PMID: 27317490.
      View in: PubMed
    55. Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE, Dinney CPN, Kamat AM, Shih YT. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 04; 3(2-3):258-264. PMID: 28753760.
      View in: PubMed
    56. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. PMID: 27376138.
      View in: PubMed
    57. Navai N, Dinney CP. Oncologic Equivalence between Laparoscopic/Robotic and Open Radical Cystectomy. J Urol. 2016 06; 195(6):1646-7. PMID: 26994308.
      View in: PubMed
    58. Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620. PMID: 26988609.
      View in: PubMed
    59. Mmeje CO, Guo CC, Shah JB, Navai N, Grossman HB, Dinney CP, Kamat AM. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. Eur Urol. 2016 11; 70(5):778-785. PMID: 26922408.
      View in: PubMed
    60. Czerniak B, Dinney C, McConkey D. Origins of Bladder Cancer. Annu Rev Pathol. 2016 05 23; 11:149-74. PMID: 26907529.
      View in: PubMed
    61. Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, Koutros S, Kiemeney LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Gago-Dominguez M, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang Z, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Ovsiannikov D, Blaszkewicz M, Castelao JE, Calaza M, Martinez ME, Cordeiro P, Xu Z, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-De-Mesquita HB, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Jeppson RP, Cancel-Tassin G, Roupret M, Comperat E, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang L, Gong Y, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Monawar Hosain GM, Schwenn M, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G, Grubb R, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF, Vineis P, Wu X, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016 Mar 15; 25(6):1203-14. PMID: 26732427.
      View in: PubMed
    62. Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke A, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol. 2016 Feb; 34(2):59.e1-8. PMID: 26421586.
      View in: PubMed
    63. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62. PMID: 26343003.
      View in: PubMed
    64. McConkey DJ, Choi W, Dinney CP. Genetic subtypes of invasive bladder cancer. Curr Opin Urol. 2015 Sep; 25(5):449-58. PMID: 26218634.
      View in: PubMed
    65. Zargar-Shoshtari K, Zargar H, Dinney CP, Ercole CE, Sharma P, Kovac E, Grivas PD, Stephenson AJ, Shah JB, Black PC, Spiess PE. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World J Urol. 2016 May; 34(5):695-701. PMID: 26286880.
      View in: PubMed
    66. Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14. PMID: 26364859.
      View in: PubMed
    67. Pierzynski JA, Hildebrandt MA, Kamat AM, Lin J, Ye Y, Dinney CP, Wu X. Genetic Variants in the Wnt/ß-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. J Urol. 2015 Dec; 194(6):1771-6. PMID: 26173102.
      View in: PubMed
    68. Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-González G, Katz RL, Wu X, Barton Grossman H, Dinney CP. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int. 2016 May; 117(5):754-60. PMID: 26032953.
      View in: PubMed
    69. Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F, Dinney CP. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. Eur Urol. 2016 02; 69(2):197-200. PMID: 26119560.
      View in: PubMed
    70. Jayaratna IS, Navai N, Dinney CP. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Transl Androl Urol. 2015 Jun; 4(3):273-82. PMID: 26816830.
      View in: PubMed
    71. Williams SB, Ye Y, Huang M, Chang DW, Kamat AM, Pu X, Dinney CP, Wu X. Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prev Res (Phila). 2015 Jul; 8(7):607-13. PMID: 25896234.
      View in: PubMed
    72. Ke HL, Lin J, Ye Y, Wu WJ, Lin HH, Wei H, Huang M, Chang DW, Dinney CP, Wu X. Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer. Ann Surg Oncol. 2015 Nov; 22(12):4104-10. PMID: 25851338.
      View in: PubMed
    73. McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CP. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):377-94, x-xi. PMID: 25836941.
      View in: PubMed
    74. Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen M, O'Donnell M, Schoenberg MP, Steinberg G. Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. Bladder Cancer. 2015 Mar 30; 1(1):29-30. PMID: 26807434.
      View in: PubMed
    75. Shu X, Purdue MP, Ye Y, Wood CG, Chen M, Wang Z, Albanes D, Pu X, Huang M, Stevens VL, Diver WR, Gapstur SM, Virtamo J, Chow WH, Tannir NM, Dinney CP, Rothman N, Chanock SJ, Wu X. Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget. 2015 Feb 28; 6(6):4097-109. PMID: 25784652.
      View in: PubMed
    76. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF. Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]. Eur Urol. 2015 Jul; 68(1):171. PMID: 26088736.
      View in: PubMed
    77. Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71. PMID: 25389341.
      View in: PubMed
    78. Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol. 2014 Nov; 32(8):1108-15. PMID: 25443274.
      View in: PubMed
    79. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9. PMID: 25257030.
      View in: PubMed
    80. Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34. PMID: 25254936.
      View in: PubMed
    81. McConkey D, Choi W, Dinney C. Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10. Eur Urol. 2015 Apr; 67(4):e76-8. PMID: 25199718.
      View in: PubMed
    82. Svatek RS, Clinton TN, Wilson CA, Kamat AM, Grossman HB, Dinney CP, Shah JB. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014 Nov; 84(5):1147-51. PMID: 25174656.
      View in: PubMed
    83. Jarow J, Kluetz PG, Lerner SP, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, Schoenberg M, Seigne J, Vikram B. Reply by the authors. Urology. 2014 Aug; 84(2):495-6. PMID: 25065996.
      View in: PubMed
    84. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC, Lecanda F, Lee KM, Lee MP, Le Marchand L, Lerner SP, Li D, Liao LM, Lim WY, Lin D, Lin J, Lindstrom S, Linet MS, Lissowska J, Liu J, Ljungberg B, Lloreta J, Lu D, Ma J, Malats N, Mannisto S, Marina N, Mastrangelo G, Matsuo K, McGlynn KA, McKean-Cowdin R, McNeill LH, McWilliams RR, Melin BS, Meltzer PS, Mensah JE, Miao X, Michaud DS, Mondul AM, Moore LE, Muir K, Niwa S, Olson SH, Orr N, Panico S, Park JY, Patel AV, Patino-Garcia A, Pavanello S, Peeters PH, Peplonska B, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Pu X, Purdue MP, Qiao YL, Rajaraman P, Riboli E, Risch HA, Rodabough RJ, Rothman N, Ruder AM, Ryu JS, Sanson M, Schned A, Schumacher FR, Schwartz AG, Schwartz KL, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Severi G, Shen H, Shen M, Shete S, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sierri S, Loon Sihoe AD, Silverman DT, Simon M, Southey MC, Spector L, Spitz M, Stampfer M, Stattin P, Stern MC, Stevens VL, Stolzenberg-Solomon RZ, Stram DO, Strom SS, Su WC, Sund M, Sung SW, Swerdlow A, Tan W, Tanaka H, Tang W, Tang ZZ, Tardon A, Tay E, Taylor PR, Tettey Y, Thomas DM, Tirabosco R, Tjonneland A, Tobias GS, Toro JR, Travis RC, Trichopoulos D, Troisi R, Truelove A, Tsai YH, Tucker MA, Tumino R, Van Den Berg D, Van Den Eeden SK, Vermeulen R, Vineis P, Visvanathan K, Vogel U, Wang C, Wang C, Wang J, Wang SS, Weiderpass E, Weinstein SJ, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolk A, Wolpin BM, Wong MP, Wrensch M, Wu C, Wu T, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Yang HP, Yang PC, Yatabe Y, Ye Y, Yeboah ED, Yin Z, Ying C, Yu CJ, Yu K, Yuan JM, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Mirabello L, Savage SA, Kraft P, Chanock SJ, Yeager M, Landi MT, Shi J, Chatterjee N, Amundadottir LT. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33. PMID: 25027329.
      View in: PubMed
    85. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014 Jul; 11(7):400-10. PMID: 24960601.
      View in: PubMed
    86. Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug; 32(6):826-32. PMID: 24931270.
      View in: PubMed
    87. McConkey DJ, Choi W, Dinney CP. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol. 2014 Oct; 66(4):609-10. PMID: 24877661.
      View in: PubMed
    88. Saxena R, Bjonnes A, Prescott J, Dib P, Natt P, Lane J, Lerner M, Cooper JA, Ye Y, Li KW, Maubaret CG, Codd V, Brackett D, Mirabello L, Kraft P, Dinney CP, Stowell D, Peyton M, Ralhan S, Wander GS, Mehra NK, Salpea KD, Gu J, Wu X, Mangino M, Hunter DJ, De Vivo I, Humphries SE, Samani NJ, Spector TD, Savage SA, Sanghera DK. Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort. Circ Cardiovasc Genet. 2014 Jun; 7(3):287-95. PMID: 24795349.
      View in: PubMed
    89. Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM. Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int. 2014 May; 113(5b):E28-33. PMID: 24053608.
      View in: PubMed
    90. Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72. PMID: 24745616.
      View in: PubMed
    91. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9. PMID: 24633966.
      View in: PubMed
    92. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65. PMID: 24525232.
      View in: PubMed
    93. Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CN. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNa/Syn3 treatment in a phase l study. Cancer Gene Ther. 2014 Mar; 21(3):91-4. PMID: 24503570.
      View in: PubMed
    94. Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014 Apr; 83(4):863-7. PMID: 24485993.
      View in: PubMed
    95. Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, Schoenberg M, Seigne J, Vikram B. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2014 Feb; 83(2):262-4. PMID: 24332121.
      View in: PubMed
    96. Abel EJ, Fisher MB, Matin SF, Kamat AM, Dinney CP, Grossman HB. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol. 2013 Nov-Dec; 39(6):817-22. PMID: 24456786.
      View in: PubMed
    97. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue M, Jacobs EJ, Albanes D, Wang Z, Deng X, Chung CC, Tang W, Bas Bueno-de-Mesquita H, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Tjønneland A, Brenan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Lerner SP, Barton Grossman H, Lin J, Gu J, Pu X, Hutchinson A, Burdette L, Wheeler W, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Schwenn M, Karagas MR, Johnson A, Schned A, Armenti KR, Hosain GM, Andriole G, Grubb R, Black A, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Haiman CA, Landi MT, Caporaso N, Fraumeni JF, Vineis P, Wu X, Silverman DT, Chanock S, Rothman N. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014 Mar 01; 23(5):1387-98. PMID: 24163127.
      View in: PubMed
    98. Wood DP. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019. PMID: 24209516.
      View in: PubMed
    99. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7. PMID: 23911605.
      View in: PubMed
    100. Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, Siefker-Radtke A. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One. 2013; 8(7):e69509. PMID: 23874968.
      View in: PubMed
    101. Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, Ashkenazi A, Czerniak B, Dinney CP, Black PC. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 2013 Jul; 12(7):1245-54. PMID: 23657946.
      View in: PubMed
    102. Wang J, Wu X, Kamat A, Barton Grossman H, Dinney CP, Lin J. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer. 2013 Jun 11; 108(11):2372-80. PMID: 23632476.
      View in: PubMed
    103. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int. 2013 Jun; 111(7):1068-74. PMID: 23551693.
      View in: PubMed
    104. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF. Phase I trial of intravesical recombinant adenovirus mediated interferon-a2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013 Sep; 190(3):850-6. PMID: 23507396.
      View in: PubMed
    105. Jäger W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, Black PC. Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol. 2013 Oct; 190(4):1404-9. PMID: 23500642.
      View in: PubMed
    106. Cheng T, Roth B, Choi W, Black PC, Dinney C, McConkey DJ. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLoS One. 2013; 8(2):e57284. PMID: 23468956.
      View in: PubMed
    107. Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, Wei H, Huang M, Chang DW, Dinney CP, Wu X. Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis. 2013 May; 34(5):1006-11. PMID: 23322153.
      View in: PubMed
    108. Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke A, Czerniak B, Dinney C, Barton M, McConkey DJ. The p63 protein isoform ?Np63a inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 2013 Feb 01; 288(5):3275-88. PMID: 23239884.
      View in: PubMed
    109. Wei H, Kamat AM, Aldousari S, Ye Y, Huang M, Dinney CP, Wu X. Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One. 2012; 7(12):e51758. PMID: 23251617.
      View in: PubMed
    110. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013 May; 189(5):1656-61. PMID: 23159581.
      View in: PubMed
    111. Chang SS, Dinney CP, Donat SM, Dahm P, Gore JL, Lotan Y, Parekh DJ, Solit DB, O'Donnell PH, Feng FY, Hansel D, Milowsky MI. 12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. Urol Oncol. 2012 Nov-Dec; 30(6):944-7. PMID: 23218073.
      View in: PubMed
    112. Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, Soloway M, Solsona E, Sved P, Babjuk M, Brausi MA, Cheng C, Comperat E, Dinney C, Otto W, Shah J, Thürof J, Witjes JA. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):36-44. PMID: 22981672.
      View in: PubMed
    113. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7. PMID: 22914978.
      View in: PubMed
    114. Dickstein RJ, Nitti G, Dinney CP, Davies BR, Kamat AM, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther. 2012 Nov; 13(13):1325-38. PMID: 22895070.
      View in: PubMed
    115. Adam L, Wszolek MF, Liu CG, Jing W, Diao L, Zien A, Zhang JD, Jackson D, Dinney CP. Plasma microRNA profiles for bladder cancer detection. Urol Oncol. 2013 Nov; 31(8):1701-8. PMID: 22863868.
      View in: PubMed
    116. Majewski T, Spiess PE, Bondaruk J, Black P, Clarke C, Benedict W, Dinney CP, Grossman HB, Tang KS, Czerniak B. Detection of bladder cancer using proteomic profiling of urine sediments. PLoS One. 2012; 7(8):e42452. PMID: 22879988.
      View in: PubMed
    117. Lee EK, Herr HW, Dickstein RJ, Kassouf W, Munsell MF, Grossman HB, Dinney CP, Kamat AM. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU Int. 2012 Dec; 110(11 Pt B):E590-5. PMID: 22758775.
      View in: PubMed
    118. Wei H, Kamat A, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin. PLoS One. 2012; 7(6):e38533. PMID: 22701660.
      View in: PubMed
    119. Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urol Oncol. 2013 Nov; 31(8):1635-42. PMID: 22575238.
      View in: PubMed
    120. Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke A, Dinney C, McConkey DJ. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther. 2012 May; 13(7):477-86. PMID: 22361733.
      View in: PubMed
    121. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13. PMID: 22564397.
      View in: PubMed
    122. Lin J, Forman MR, Wang J, Grossman HB, Chen M, Dinney CP, Hawk ET, Wu X. Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. Int J Cancer. 2012 Oct 15; 131(8):1892-903. PMID: 22261697.
      View in: PubMed
    123. Chang J, Dinney CP, Huang M, Wu X, Gu J. Genetic variants in telomere-maintenance genes and bladder cancer risk. PLoS One. 2012; 7(2):e30665. PMID: 22363464.
      View in: PubMed
    124. Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. J Urol. 2012 Mar; 187(3):862-7. PMID: 22245325.
      View in: PubMed
    125. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012; 7(1):e30206. PMID: 22253920.
      View in: PubMed
    126. Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, Shariat SF. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World J Urol. 2012 Dec; 30(6):753-9. PMID: 22009117.
      View in: PubMed
    127. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Grossman HB, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Fraumeni JF, Silverman DT, Chanock SJ, Wu X. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011 Nov 01; 20(21):4282-9. PMID: 21824976.
      View in: PubMed
    128. Xing J, Dinney CP, Shete S, Huang M, Hildebrandt MA, Chen Z, Gu J. Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. Cancer. 2012 Jan 01; 118(1):205-15. PMID: 21692063.
      View in: PubMed
    129. Yang Z, Zhang XQ, Dinney CN, Benedict WF. Direct cytotoxicity produced by adenoviral-mediated interferon a gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation. Cancer Gene Ther. 2011 Sep; 18(9):609-16. PMID: 21681220.
      View in: PubMed
    130. Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Montorsi F, Müller SC, Fritsche HM, Sonpavde G, Tilki D, Isbarn H, Ficarra V, Dinney CP, Shariat SF. Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int. 2011; 87(1):42-8. PMID: 21659717.
      View in: PubMed
    131. Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6. PMID: 21478035.
      View in: PubMed
    132. Gu J, Chen M, Shete S, Amos CI, Kamat A, Ye Y, Lin J, Dinney CP, Wu X. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila). 2011 Apr; 4(4):514-21. PMID: 21460395.
      View in: PubMed
    133. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011 Oct; 108(7):1119-23. PMID: 21426474.
      View in: PubMed
    134. Shah JB, McConkey DJ, Dinney CP. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res. 2011 May 01; 17(9):2608-12. PMID: 21415213.
      View in: PubMed
    135. Fernández MI, Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP, Kamat AM. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol. 2012 Nov-Dec; 30(6):821-4. PMID: 21396845.
      View in: PubMed
    136. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011 Jul; 78(1):61-7. PMID: 21354598.
      View in: PubMed
    137. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, Ficarra V, Dinney CP, Lotan Y, Fradet Y, Shariat SF. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011 Apr; 185(4):1216-21. PMID: 21334687.
      View in: PubMed
    138. Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011 Mar; 107(6):898-904. PMID: 21244604.
      View in: PubMed
    139. Black PC, Brown GA, Dinney CP, Kassouf W, Inamoto T, Arora A, Gallagher D, Munsell MF, Bar-Eli M, McConkey DJ, Adam L. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol. 2011 Feb; 185(2):693-700. PMID: 21168861.
      View in: PubMed
    140. Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, Schoenberg M, Sagalowsky AI, Lotan Y, Shariat SF. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61. PMID: 21167527.
      View in: PubMed
    141. Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, McConkey DJ, Hazle JD, Dinney CP. Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int. 2010 Dec; 106(11):1799-804. PMID: 20500508.
      View in: PubMed
    142. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Ficarra V, Dinney CP, Lotan Y, Fradet Y, Shariat SF. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2011 Sep; 108(5):687-92. PMID: 21087453.
      View in: PubMed
    143. Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, Munsell MF, Kamat AM. Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol. 2011 Jan; 185(1):79-83. PMID: 21074799.
      View in: PubMed
    144. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF, Silverman DT, Chanock SJ. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010 Nov; 42(11):978-84. PMID: 20972438.
      View in: PubMed
    145. Xu AD, Ng CS, Kamat A, Grossman HB, Dinney C, Sandler CM. Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. AJR Am J Roentgenol. 2010 Oct; 195(4):959-65. PMID: 20858825.
      View in: PubMed
    146. Svatek RS, Shah JB, Xing J, Chang D, Lin J, McConkey DJ, Wu X, Dinney CP. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010 Oct 01; 116(19):4513-9. PMID: 20572047.
      View in: PubMed
    147. Sundi D, Svatek RS, Margulis V, Wood CG, Matin SF, Dinney CP, Kamat AM. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol. 2012 May-Jun; 30(3):266-72. PMID: 20869888.
      View in: PubMed
    148. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila). 2010 Oct; 3(10):1235-45. PMID: 20858759.
      View in: PubMed
    149. Lim EK, Yang J, Dinney CP, Suh JS, Huh YM, Haam S. Self-assembled fluorescent magnetic nanoprobes for multimode-biomedical imaging. Biomaterials. 2010 Dec; 31(35):9310-9. PMID: 20851463.
      View in: PubMed
    150. Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, Schoenberg M, Stief CG, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Reich O, Shariat SF. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol. 2010 Sep; 184(3):888-94. PMID: 20643448.
      View in: PubMed
    151. Hegarty PK, Dinney CP, Pettaway CA. Controversies in ilioinguinal lymphadenectomy. Urol Clin North Am. 2010 Aug; 37(3):421-34. PMID: 20674697.
      View in: PubMed
    152. Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7. PMID: 20651056.
      View in: PubMed
    153. Grossman HB, Dinney CP, Schmitz-Dräger BJ, Goebell PJ. The International Bladder Cancer Network. Urol Oncol. 2010 Jul-Aug; 28(4):375-6. PMID: 20610275.
      View in: PubMed
    154. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C, Czerniak B. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol. 2010 Jul-Aug; 28(4):429-40. PMID: 20610280.
      View in: PubMed
    155. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010 Jul 01; 116(13):3127-34. PMID: 20564621.
      View in: PubMed
    156. Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 2010 Aug; 31(8):1387-91. PMID: 20530239.
      View in: PubMed
    157. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, Lerner SP, Schoenberg M, Volkmer BG, Sagalowsky AI, Shariat SF. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010 Jun; 183(6):2165-70. PMID: 20399473.
      View in: PubMed
    158. Svatek RS, Fisher MB, Williams MB, Matin SF, Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Dinney CP. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology. 2010 Dec; 76(6):1419-24. PMID: 20472264.
      View in: PubMed
    159. Zlotta AR, Cohen SM, Dinney C, Droller M, van der Kwast TH, van Rhijn BW, Bochner B, Ameil G, Jewett MA. BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):329-33. PMID: 20439032.
      View in: PubMed
    160. Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol. 2011 Mar-Apr; 29(2):157-61. PMID: 20456984.
      View in: PubMed
    161. Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Dinney CP, Hawk ET, Wu X. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res (Phila). 2010 Apr; 3(4):505-17. PMID: 20354165.
      View in: PubMed
    162. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12. PMID: 20132195.
      View in: PubMed
    163. Svatek RS, Fisher MB, Matin SF, Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Kennedy KA, Dinney CP. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol. 2010 Mar; 183(3):929-34. PMID: 20083264.
      View in: PubMed
    164. Inamoto T, Czerniak BA, Dinney CP, Kamat AM. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer. 2010 Jan 15; 116(2):340-6. PMID: 19908257.
      View in: PubMed
    165. Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, Schoenberg M, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan; 183(1):87-93. PMID: 19942232.
      View in: PubMed
    166. Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL. Management of urethral recurrence after orthotopic urinary diversion. BJU Int. 2010 Jul; 106(1):56-61. PMID: 20002676.
      View in: PubMed
    167. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009 Dec; 28(3-4):335-44. PMID: 20012924.
      View in: PubMed
    168. McConkey DJ, Dinney C. Urological cancers. Preface. Cancer Metastasis Rev. 2009 Dec; 28(3-4):267. PMID: 20013034.
      View in: PubMed
    169. McConkey DJ, Dinney CP. The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition. Cancer Prev Res (Phila). 2009 Dec; 2(12):1001-2. PMID: 19952365.
      View in: PubMed
    170. Svatek RS, Siefker-Radtke A, Dinney CP. Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J. 2009 Dec; 3(6 Suppl 4):S228-31. PMID: 20019991.
      View in: PubMed
    171. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu X. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009 Dec; 30(12):2047-52. PMID: 19875696.
      View in: PubMed
    172. Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009 Dec 01; 27(34):5680-4. PMID: 19858384.
      View in: PubMed
    173. Rostro-Kohanloo BC, Bickford LR, Payne CM, Day ES, Anderson LJ, Zhong M, Lee S, Mayer KM, Zal T, Adam L, Dinney CP, Drezek RA, West JL, Hafner JH. The stabilization and targeting of surfactant-synthesized gold nanorods. Nanotechnology. 2009 Oct 28; 20(43):434005. PMID: 19801751.
      View in: PubMed
    174. Svatek RS, Dinney CP. Words of wisdom. Re: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. Eur Urol. 2009 Oct; 56(4):745-6. PMID: 19995527.
      View in: PubMed
    175. Fisher MB, Svatek RS, Hegarty PK, McGinniss JE, Hightower C, Grossman HB, Kamat AM, Dinney CP, Matin SF. Cardiac history and risk of post-cystectomy cardiac complications. Urology. 2009 Nov; 74(5):1085-9. PMID: 19758689.
      View in: PubMed
    176. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9. PMID: 19766384.
      View in: PubMed
    177. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009 Aug 15; 15(16):5060-72. PMID: 19671845.
      View in: PubMed
    178. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, Dinney CP, Czerniak B, Zhang ZF, Kiltie AE, Bishop DT, Vineis P, Porru S, Buntinx F, Kellen E, Zeegers MP, Kumar R, Rudnai P, Gurzau E, Koppova K, Mayordomo JI, Sanchez M, Saez B, Lindblom A, de Verdier P, Steineck G, Mills GB, Schned A, Guarrera S, Polidoro S, Chang SC, Lin J, Chang DW, Hale KS, Majewski T, Grossman HB, Thorlacius S, Thorsteinsdottir U, Aben KK, Witjes JA, Stefansson K, Amos CI, Karagas MR, Gu J. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009 Sep; 41(9):991-5. PMID: 19648920.
      View in: PubMed
    179. Svatek RS, Dinney CP. Words of wisdom. Re: Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. Lotan Y, Shariat SF; NMP22 Study Group. BJU Int 2008;101:1362-7. Eur Urol. 2009 Jul; 56(1):217-8. PMID: 19995517.
      View in: PubMed
    180. Lin J, Kamat A, Gu J, Chen M, Dinney CP, Forman MR, Wu X. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2090-7. PMID: 19549811.
      View in: PubMed
    181. Svatek RS, Kamat AM, Dinney CP. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009 Jun; 9(6):807-13. PMID: 19496717.
      View in: PubMed
    182. Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat A, Bassett R, Dinney CP, Czerniak BA. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct; 40(10):1448-52. PMID: 19454359.
      View in: PubMed
    183. Svatek RS, Avritscher EB, Elting L, Dinney CP. High risk populations and cystectomy outcomes. J Urol. 2009 Jul; 182(1):10-1. PMID: 19450857.
      View in: PubMed
    184. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009 Jun 01; 27(16):2592-7. PMID: 19414678.
      View in: PubMed
    185. Matin SF, Feeley T, Kennamer D, Corriere JN, Miles M, Kays C, Green H, Craig CE, Dinney CP. Office cystoscopy and transrectal ultrasound-guided prostate biopsies pose minimal risk: prospective evaluation of 921 procedures. Urology. 2009 Jun; 73(6):1175-8. PMID: 19362332.
      View in: PubMed
    186. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 2009 Jan; 73(1):147-52. PMID: 18848348.
      View in: PubMed
    187. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst. 2008 Oct 01; 100(19):1401-11. PMID: 18812553.
      View in: PubMed
    188. Dinney CP. Bladder cancer. Urol Oncol. 2008 Sep-Oct; 26(5):479-80. PMID: 18774458.
      View in: PubMed
    189. Gu J, Horikawa Y, Chen M, Dinney CP, Wu X. Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2445-50. PMID: 18768515.
      View in: PubMed
    190. Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T, Gallagher D, Bar-Eli M, McConkey DJ, Adam L, Dinney CP. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 2008 Sep; 180(3):1146-53. PMID: 18639280.
      View in: PubMed
    191. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008 Jun; 112(11):2467-74. PMID: 18361427.
      View in: PubMed
    192. Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol. 2008 Jul; 180(1):164-7; discussion 167. PMID: 18485384.
      View in: PubMed
    193. Liang D, Lin J, Grossman HB, Ma J, Wei B, Dinney CP, Wu X. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control. 2008 Nov; 19(9):981-92. PMID: 18478342.
      View in: PubMed
    194. Majewski T, Lee S, Jeong J, Yoon DS, Kram A, Kim MS, Tuziak T, Bondaruk J, Lee S, Park WS, Tang KS, Chung W, Shen L, Ahmed SS, Johnston DA, Grossman HB, Dinney CP, Zhou JH, Harris RA, Snyder C, Filipek S, Narod SA, Watson P, Lynch HT, Gazdar A, Bar-Eli M, Wu XF, McConkey DJ, Baggerly K, Issa JP, Benedict WF, Scherer SE, Czerniak B. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 2008 Jul; 88(7):694-721. PMID: 18458673.
      View in: PubMed
    195. Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res. 2008 Apr 01; 14(7):2236-44. PMID: 18381966.
      View in: PubMed
    196. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 2008 Apr 01; 68(7):2530-7. PMID: 18381463.
      View in: PubMed
    197. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 01; 14(5):1478-86. PMID: 18316572.
      View in: PubMed
    198. Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS. Clinical model of cost of bladder cancer in the elderly. Urology. 2008 Mar; 71(3):519-25. PMID: 18342201.
      View in: PubMed
    199. Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol. 2009 Jan-Feb; 27(1):3-7. PMID: 18367107.
      View in: PubMed
    200. Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep. 2008 Jan; 9(1):55-61. PMID: 18366975.
      View in: PubMed
    201. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9. PMID: 18172274.
      View in: PubMed
    202. Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008 Jan 01; 26(1):121-6. PMID: 18165646.
      View in: PubMed
    203. Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. Cancer Metastasis Rev. 2007 Dec; 26(3-4):623-34. PMID: 17726580.
      View in: PubMed
    204. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008 Jan; 179(1):353-8. PMID: 18006009.
      View in: PubMed
    205. Wu X, Lin J, Grossman HB, Huang M, Gu J, Etzel CJ, Amos CI, Dinney CP, Spitz MR. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol. 2007 Nov 01; 25(31):4974-81. PMID: 17971596.
      View in: PubMed
    206. Zhu Y, Yang H, Chen Q, Lin J, Grossman HB, Dinney CP, Wu X, Gu J. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst). 2008 Feb 01; 7(2):141-8. PMID: 17923445.
      View in: PubMed
    207. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007 Dec; 178(6):2302-6; discussion 2307. PMID: 17936803.
      View in: PubMed
    208. Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, Gleave ME, So AI. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int. 2007 Dec; 100(6):1377-84. PMID: 17850390.
      View in: PubMed
    209. Black PC, Agarwal PK, Dinney CP. Targeted therapies in bladder cancer--an update. Urol Oncol. 2007 Sep-Oct; 25(5):433-8. PMID: 17826665.
      View in: PubMed
    210. Agarwal PK, Black PC, McConkey DJ, Dinney CP. Emerging drugs for targeted therapy of bladder cancer. Expert Opin Emerg Drugs. 2007 Sep; 12(3):435-48. PMID: 17874971.
      View in: PubMed
    211. Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology. 2007 Sep; 70(3):473-6. PMID: 17905099.
      View in: PubMed
    212. Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, Wu X, Gu J. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007 Oct; 28(10):2160-5. PMID: 17728339.
      View in: PubMed
    213. Shao L, Wood CG, Zhang D, Tannir NM, Matin S, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007 Oct; 178(4 Pt 1):1492-6. PMID: 17707063.
      View in: PubMed
    214. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9. PMID: 17614317.
      View in: PubMed
    215. Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, Colin D, Bar-Eli M. Targeting EGFR in bladder cancer. World J Urol. 2007 Dec; 25(6):573-9. PMID: 17690890.
      View in: PubMed
    216. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007 Aug; 70(2):252-6. PMID: 17826484.
      View in: PubMed
    217. Lin X, Wood CG, Shao L, Huang M, Yang H, Dinney CP, Wu X. Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer. 2007 Jul 15; 110(2):282-8. PMID: 17549681.
      View in: PubMed
    218. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007 Jul 01; 110(1):62-7. PMID: 17542024.
      View in: PubMed
    219. Black PC, Brown GA, Dinney CP. Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. Expert Rev Anticancer Ther. 2007 Jul; 7(7):1015-26. PMID: 17627461.
      View in: PubMed
    220. Zhao H, Lin J, Grossman HB, Hernandez LM, Dinney CP, Wu X. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. Int J Cancer. 2007 May 15; 120(10):2208-13. PMID: 17290402.
      View in: PubMed
    221. Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res. 2007 May 01; 13(9):2614-20. PMID: 17473191.
      View in: PubMed
    222. Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol. 2007 May; 177(5):1900-6. PMID: 17437845.
      View in: PubMed
    223. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007 Sep; 52(3):769-74. PMID: 17434254.
      View in: PubMed
    224. Black PC, Dinney CP. Re: Nomograms provide improved accuracy for predicting survival after radical cystectomy. Eur Urol. 2007 Apr; 51(4):1140-1. PMID: 17415911.
      View in: PubMed
    225. Papageorgiou A, Dinney CP, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther. 2007 Jun; 6(6):872-9. PMID: 17617740.
      View in: PubMed
    226. Soloway M. High-grade T1 bladder cancer at the ureterovesical junction. Curr Urol Rep. 2007 Mar; 8(2):104-7. PMID: 17303014.
      View in: PubMed
    227. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 2007 Feb 15; 67(4):1430-5. PMID: 17308080.
      View in: PubMed
    228. Huang M, Dinney CP, Lin X, Lin J, Grossman HB, Wu X. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2007 Jan; 16(1):84-91. PMID: 17220334.
      View in: PubMed
    229. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007 Jan; 6(1):277-85. PMID: 17237287.
      View in: PubMed
    230. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol. 2007 Jan-Feb; 25(1):38-45. PMID: 17208137.
      View in: PubMed
    231. Wu X, Lin X, Dinney CP, Gu J, Grossman HB. Genetic polymorphism in bladder cancer. Front Biosci. 2007 Jan 01; 12:192-213. PMID: 17127293.
      View in: PubMed
    232. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006 Dec 15; 66(24):11644-8. PMID: 17178858.
      View in: PubMed
    233. Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol. 2006 Dec 10; 24(35):5528-35. PMID: 17158538.
      View in: PubMed
    234. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006 Dec; 98(6):1176-80. PMID: 17125474.
      View in: PubMed
    235. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 2006 Dec; 5(12):3032-41. PMID: 17172406.
      View in: PubMed
    236. Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J Urol. 2006 Nov; 24(5):531-42. PMID: 17115230.
      View in: PubMed
    237. Zhu Y, Lai M, Yang H, Lin J, Huang M, Grossman HB, Dinney CP, Wu X. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 2007 Mar; 28(3):698-703. PMID: 17052994.
      View in: PubMed
    238. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer. 2006 Oct 01; 107(7):1491-5. PMID: 16894527.
      View in: PubMed
    239. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol. 2006 Oct; 176(4 Pt 1):1463-7. PMID: 16952661.
      View in: PubMed
    240. Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol. 2006 Oct; 176(4 Pt 1):1642-7. PMID: 16952707.
      View in: PubMed
    241. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006 Sep; 68(3):549-53. PMID: 16979735.
      View in: PubMed
    242. Lin J, Dinney CP, Grossman HB, Jhamb M, Zhu Y, Spitz MR, Wu X. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet. 2006 Sep; 70(3):240-5. PMID: 16922727.
      View in: PubMed
    243. Lin J, Dinney CP, Grossman HB, Wu X. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer Epidemiol Biomarkers Prev. 2006 Sep; 15(9):1746-9. PMID: 16985040.
      View in: PubMed
    244. Black PC, Brown GA, Dinney CP. Should cystectomy only be performed at high-volume hospitals by high-volume surgeons? Curr Opin Urol. 2006 Sep; 16(5):344-9. PMID: 16905980.
      View in: PubMed
    245. Kamat AM, Dinney CP. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol. 2006 Sep; 3(9):472-3. PMID: 16964186.
      View in: PubMed
    246. Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, Wu X. Bladder cancer risk as modified by family history and smoking. Cancer. 2006 Aug 15; 107(4):705-11. PMID: 16845665.
      View in: PubMed
    247. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006 Aug 01; 12(15):4671-7. PMID: 16899617.
      View in: PubMed
    248. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol. 2006 Aug; 176(2):787-92. PMID: 16813948.
      View in: PubMed
    249. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol. 2006 Jul; 176(1):53-7; discussion 57. PMID: 16753366.
      View in: PubMed
    250. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun; 175(6):2058-62. PMID: 16697803.
      View in: PubMed
    251. Carmack AJ, Soloway MS. The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology. 2006 Mar; 67(3 Suppl 1):3-8; discussion 8-10. PMID: 16530066.
      View in: PubMed
    252. Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 2006 Mar; 67(3):466-71. PMID: 16527559.
      View in: PubMed
    253. Grossman HB, Blute ML, Dinney CP, Jones JS, Liou LS, Reuter VE, Soloway MS. The use of urine-based biomarkers in bladder cancer. Urology. 2006 Mar; 67(3 Suppl 1):62-4. PMID: 16530080.
      View in: PubMed
    254. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006 Mar; 175(3 Pt 1):881-5. PMID: 16469571.
      View in: PubMed
    255. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology. 2006 Mar; 67(3):518-23. PMID: 16527570.
      View in: PubMed
    256. Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urology. 2006 Mar; 67(3 Suppl 1):25-33; discussion 33-4. PMID: 16530072.
      View in: PubMed
    257. Jones JS. DNA-based molecular cytology for bladder cancer surveillance. Urology. 2006 Mar; 67(3 Suppl 1):35-45; discussion 45-7. PMID: 16530074.
      View in: PubMed
    258. Reuter VE. The pathology of bladder cancer. Urology. 2006 Mar; 67(3 Suppl 1):11-7; discussion 17-8. PMID: 16530068.
      View in: PubMed
    259. Dinney CP. Therapy of invasive bladder cancer. Urology. 2006 Mar; 67(3 Suppl 1):56-9; discussion 60-1. PMID: 16530078.
      View in: PubMed
    260. Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, Benedict WF. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther. 2006 Feb; 13(2):125-30. PMID: 16082384.
      View in: PubMed
    261. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar; 78(3):464-79. PMID: 16465622.
      View in: PubMed
    262. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005 Nov 15; 65(22):10524-35. PMID: 16288045.
      View in: PubMed
    263. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia. 2005 Oct; 7(10):912-20. PMID: 16242074.
      View in: PubMed
    264. Gu J, Grossman HB, Dinney CP, Wu X. The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics. 2005 Sep; 6(6):575-84. PMID: 16142998.
      View in: PubMed
    265. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, Saldin K, Dinney CP. Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer. 2005 Sep 01; 104(5):975-84. PMID: 16044400.
      View in: PubMed
    266. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20; 23(24):5746-56. PMID: 16110031.
      View in: PubMed
    267. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate. 2005 Jun 15; 64(1):40-9. PMID: 15651067.
      View in: PubMed
    268. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 2005 Jun 01; 65(11):4902-8. PMID: 15930312.
      View in: PubMed
    269. Gu J, Spitz MR, Zhao H, Lin J, Grossman HB, Dinney CP, Wu X. Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. Carcinogenesis. 2005 Oct; 26(10):1741-7. PMID: 15905204.
      View in: PubMed
    270. Adam L, Kassouf W, Dinney CP. Clinical applications for targeted therapy in bladder cancer. Urol Clin North Am. 2005 May; 32(2):239-46, vii. PMID: 15862621.
      View in: PubMed
    271. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, Fuller G, Dinney C, Grossman HB, Baggerly K, Zhang W, Czerniak B. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest. 2005 Apr; 85(4):532-49. PMID: 15778693.
      View in: PubMed
    272. Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, Wu X. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1408-15. PMID: 15746040.
      View in: PubMed
    273. Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ. Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):413-5. PMID: 15701822.
      View in: PubMed
    274. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, McConkey DJ. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res. 2004 Dec 15; 64(24):8973-9. PMID: 15604261.
      View in: PubMed
    275. Gabril M, Xuan J, Moussa M, Dinney CP, Chin JL, Izawa JI. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model. Urology. 2004 Dec; 64(6):1233-7. PMID: 15596214.
      View in: PubMed
    276. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004 Sep; 10(3):525-32. PMID: 15336652.
      View in: PubMed
    277. Highshaw RA, McConkey DJ, Dinney CP. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Curr Opin Urol. 2004 Sep; 14(5):295-300. PMID: 15300150.
      View in: PubMed
    278. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004 Aug 15; 22(16):3316-22. PMID: 15310775.
      View in: PubMed
    279. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell. 2004 Aug; 6(2):111-6. PMID: 15324694.
      View in: PubMed
    280. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004 Aug; 172(2):481-4. PMID: 15247709.
      View in: PubMed
    281. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res. 2004 Jul 01; 64(13):4601-10. PMID: 15231672.
      View in: PubMed
    282. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004 Mar; 3(3):279-90. PMID: 15026548.
      View in: PubMed
    283. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, Dinney CP. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004 Feb; 171(2 Pt 1):570-4. PMID: 14713761.
      View in: PubMed
    284. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol. 2003 Dec; 170(6 Pt 1):2221-4. PMID: 14634383.
      View in: PubMed
    285. Pagliaro LC, Keyhani A, Liu B, Perrotte P, Wilson D, Dinney CP. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol. 2003 Nov-Dec; 21(6):456-62. PMID: 14693272.
      View in: PubMed
    286. Canfield SE, Dinney CP, Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am. 2003 Nov; 30(4):791-802. PMID: 14680315.
      View in: PubMed
    287. Grossman HB, Dinney CP. If cystectomy is insufficient, what is an urologist to do? Urol Oncol. 2003 Nov-Dec; 21(6):475-8. PMID: 14693276.
      View in: PubMed
    288. Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol. 2003 Sep-Oct; 21(5):327-33. PMID: 14670538.
      View in: PubMed
    289. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res. 2003 Aug 01; 9(8):3167-75. PMID: 12912969.
      View in: PubMed
    290. Sweeney P, Karashima T, Ishikura H, Wiehle S, Yamashita M, Benedict WF, Cristiano RJ, Dinney CP. Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. Cancer Res. 2003 Jul 15; 63(14):4017-20. PMID: 12874000.
      View in: PubMed
    291. Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, Dinney CP. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003 Jul; 9(7):2786-97. PMID: 12855659.
      View in: PubMed
    292. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S85-104. PMID: 12850530.
      View in: PubMed
    293. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003 Jun 15; 21(12):2247-53. PMID: 12805322.
      View in: PubMed
    294. Rosser CJ, Slaton JW, Izawa JI, Levy LB, Dinney CP. Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology. 2003 Jun; 61(6):1151-5. PMID: 12809885.
      View in: PubMed
    295. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol. 2003 Jun; 169(6):2113-7. PMID: 12771730.
      View in: PubMed
    296. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, Wu X. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst. 2003 Apr 02; 95(7):540-7. PMID: 12671022.
      View in: PubMed
    297. Kedar D, Baker CH, Killion JJ, Dinney CP, Fidler IJ. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 2002 Nov; 8(11):3592-600. PMID: 12429651.
      View in: PubMed
    298. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D, Fidler IJ, Dinney CP, Killion JJ. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res. 2002 Oct 15; 62(20):5720-6. PMID: 12384530.
      View in: PubMed
    299. Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther. 2002 Aug; 9(8):687-91. PMID: 12136430.
      View in: PubMed
    300. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res. 2002 Aug; 8(8):2714-24. PMID: 12171905.
      View in: PubMed
    301. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res. 2002 Jun; 8(6):1863-70. PMID: 12060629.
      View in: PubMed
    302. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res. 2002 May; 8(5):1253-64. PMID: 12006546.
      View in: PubMed
    303. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer. 2002 Apr 10; 98(5):682-9. PMID: 11920636.
      View in: PubMed
    304. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res. 2002 Apr; 8(4):1258-70. PMID: 11948141.
      View in: PubMed
    305. Rosser CJ, Benedict WF, Dinney CP. Gene therapy for superficial bladder cancer. Expert Rev Anticancer Ther. 2001 Dec; 1(4):531-9. PMID: 12113085.
      View in: PubMed
    306. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001 Oct 15; 19(20):4005-13. PMID: 11600601.
      View in: PubMed
    307. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res. 2001 Sep; 7(9):2840-53. PMID: 11555602.
      View in: PubMed
    308. Inoue K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP. Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol Rep. 2001 Sep-Oct; 8(5):955-64. PMID: 11496299.
      View in: PubMed
    309. Lance RS, Dinney CP, Swanson D, Babaian RJ, Pisters LL, Palmer LJ, Grossman HB. Radical cystectomy for invasive bladder cancer in the octogenarian. Oncol Rep. 2001 Jul-Aug; 8(4):723-6. PMID: 11410772.
      View in: PubMed
    310. Slaton JW, Benedict WF, Dinney CP. P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology. 2001 May; 57(5):852-9. PMID: 11337281.
      View in: PubMed
    311. Mendelsohn J, Dinney CP. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol. 2001 Apr; 165(4):1152-7. PMID: 11257658.
      View in: PubMed
    312. Izawa JI, Dinney CP. The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ. 2001 Mar 06; 164(5):662-70. PMID: 11258215.
      View in: PubMed
    313. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001 Feb; 158(2):735-43. PMID: 11159211.
      View in: PubMed
    314. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, Dinney CP. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep. 2001 Jan-Feb; 8(1):9-15. PMID: 11115562.
      View in: PubMed
    315. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 2000 Dec; 6(12):4874-84. PMID: 11156247.
      View in: PubMed
    316. Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000 Dec; 6(12):4866-73. PMID: 11156246.
      View in: PubMed
    317. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res. 2000 Nov; 6(11):4422-31. PMID: 11106263.
      View in: PubMed
    318. Perrotte P, Wood M, Slaton JW, Wilson DR, Pagliaro L, Price RE, Dinney CP. Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology. 2000 Jul; 56(1):155-9. PMID: 10869658.
      View in: PubMed
    319. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, Dinney CP. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 2000 Jul; 6(7):2635-43. PMID: 10914704.
      View in: PubMed
    320. Pisters LL, English SF, Scott SM, Westney OL, Dinney CP, McGuire EJ. Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy. J Urol. 2000 Jun; 163(6):1771-4. PMID: 10799179.
      View in: PubMed
    321. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000 May; 6(5):2104-19. PMID: 10815938.
      View in: PubMed
    322. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000 Apr 15; 60(8):2290-9. PMID: 10786697.
      View in: PubMed
    323. Hsieh JT, Dinney CP, Chung LW. The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am. 2000 Feb; 27(1):103-13, ix. PMID: 10696249.
      View in: PubMed
    324. Grossman HB, Dinney CP. Markers of bladder cancer State of the art. Urol Oncol. 2000 Jan-Feb; 5(1):3-10. PMID: 21227279.
      View in: PubMed
    325. Balbay MD, Slaton JW, Trane N, Skibber J, Dinney CP. Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. Cancer. 1999 Dec 01; 86(11):2212-6. PMID: 10590359.
      View in: PubMed
    326. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999 Oct; 5(10):2726-34. PMID: 10537335.
      View in: PubMed
    327. Slaton JW, Swanson DA, Grossman HB, Dinney CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1999 Sep; 162(3 Pt 1):710-4. PMID: 10458349.
      View in: PubMed
    328. Wood M, Perrotte P, Onishi E, Harper ME, Dinney C, Pagliaro L, Wilson DR. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther. 1999 Jul-Aug; 6(4):367-72. PMID: 10419055.
      View in: PubMed
    329. Hughes JH, Katz RL, Rodriguez-Villanueva J, Kidd L, Dinney C, Grossman HB, Fritsche HA. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol. 1999 May; 20(5):285-90. PMID: 10319229.
      View in: PubMed
    330. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res. 1999 Apr; 5(4):783-9. PMID: 10213213.
      View in: PubMed
    331. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D, Fidler IJ. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res. 1999 Feb 15; 59(4):872-9. PMID: 10029078.
      View in: PubMed
    332. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999 Feb; 5(2):257-65. PMID: 10037173.
      View in: PubMed
    333. Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, Troncoso P. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol. 1999 Feb; 161(2):509-14. PMID: 9915437.
      View in: PubMed
    334. Dinney CP, Babkowski RC, Antelo M, Perrotte P, Liebert M, Zhang HZ, Palmer J, Veltri RW, Katz RL, Grossman HB. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol. 1998 Oct; 160(4):1285-90. PMID: 9751337.
      View in: PubMed
    335. Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CP. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol. 1998 Apr; 159(4):1168-73. PMID: 9507824.
      View in: PubMed
    336. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998 Apr; 4(4):829-34. PMID: 9563875.
      View in: PubMed
    337. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998 Apr; 159(4):1163-7. PMID: 9507823.
      View in: PubMed
    338. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998 Mar; 159(3):792-5. PMID: 9474150.
      View in: PubMed
    339. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998 Feb 15; 58(4):808-14. PMID: 9485039.
      View in: PubMed
    340. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol. 1998 Feb; 159(2):394-8. PMID: 9649246.
      View in: PubMed
    341. Gohji K, Nakajima M, Boyd D, Dinney CP, Bucana CD, Kitazana S, Kamidono S, Fidler IJ. Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells. Am J Pathol. 1997 Dec; 151(6):1655-61. PMID: 9403716.
      View in: PubMed
    342. Slaton JW, Balbay MD, Levy DA, Pisters LL, Nesbitt JC, Swanson DA, Dinney CP. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Urology. 1997 Nov; 50(5):673-7. PMID: 9372873.
      View in: PubMed
    343. Pollack A, Czerniak B, Zagars GK, Hu SX, Wu CS, Dinney CP, Chyle V, Benedict WF. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1997 Oct 01; 39(3):687-95. PMID: 9336151.
      View in: PubMed
    344. Ghayee H, Dinney C, Pathak S. Do lymphocytes contain chromosomal lesions that are also stable markers in cancer cells? Int J Oncol. 1997 Oct; 11(4):681-4. PMID: 21528261.
      View in: PubMed
    345. Slaton JW, Dinney CP, Veltri RW, Miller CM, Liebert M, O'Dowd GJ, Grossman HB. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol. 1997 Sep; 158(3 Pt 1):806-11. PMID: 9258087.
      View in: PubMed
    346. Nesbitt JC, Soltero ER, Dinney CP, Walsh GL, Schrump DS, Swanson DA, Pisters LL, Willis KD, Putnam JB. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg. 1997 Jun; 63(6):1592-600. PMID: 9205155.
      View in: PubMed
    347. Chen ME, Pisters LL, Malpica A, Pettaway CA, Dinney CP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. J Urol. 1997 Jun; 157(6):2120-3. PMID: 9146596.
      View in: PubMed
    348. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, Babaian RJ. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997 Mar; 157(3):921-5. PMID: 9072600.
      View in: PubMed
    349. Dinney CP, Parker C, Dong Z, Fan D, Eve BY, Bucana C, Radinsky R. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res. 1997 Feb; 3(2):161-8. PMID: 9815668.
      View in: PubMed
    350. Corral DA, Dinney CP. Radical cystectomy: posterior dissection following prior therapy. J Surg Oncol. 1997 Feb; 64(2):165-6. PMID: 9047257.
      View in: PubMed
    351. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1997 Jan 01; 37(1):41-9. PMID: 9054875.
      View in: PubMed
    352. Kleinerman DI, Dinney CP, Zhang WW, Lin SH, Van NT, Hsieh JT. Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. Cancer Res. 1996 Aug 01; 56(15):3431-5. PMID: 8758907.
      View in: PubMed
    353. Hall MC, Swanson DA, Dinney CP. Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Urology. 1996 Jun; 47(6):826-30. PMID: 8677571.
      View in: PubMed
    354. Hall CM, Dinney CP. Radical cystectomy for stage T3b bladder cancer. Semin Urol Oncol. 1996 May; 14(2):73-80. PMID: 8734734.
      View in: PubMed
    355. de la Roza GL, Hopkovitz A, Caraway NP, Kidd L, Dinney CP, Johnston D, Katz RL. DNA image analysis of urinary cytology: prediction of recurrent transitional cell carcinoma. Mod Pathol. 1996 May; 9(5):571-8. PMID: 8733774.
      View in: PubMed
    356. Millikan R, Dinney CP. The role of chemotherapy in the management of the patient with T3b bladder cancer. Semin Urol Oncol. 1996 May; 14(2):81-5. PMID: 8734735.
      View in: PubMed
    357. Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala A, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol. 1996 Apr; 155(4):1241-5. PMID: 8632540.
      View in: PubMed
    358. Wu CS, Pollack A, Czerniak B, Chyle V, Zagars GK, Dinney CP, Hu SX, Benedict WF. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology. 1996 Mar; 47(3):305-10. PMID: 8633392.
      View in: PubMed
    359. Kenworthy P, Tanguay S, Dinney CP. The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol. 1996 Feb; 155(2):501-3. PMID: 8558645.
      View in: PubMed
    360. Tanguay S, Pisters LL, Lawrence DD, Dinney CP. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol. 1996 Jan; 155(1):26-9. PMID: 7490850.
      View in: PubMed
    361. Balat O, Kudelka AP, Ro JY, Edwards CL, Balbay D, Dinney C, Kavanagh JJ. Two synchronous primary tumors of the ovary and kidney: a case report. Eur J Gynaecol Oncol. 1996; 17(4):257-9. PMID: 8856298.
      View in: PubMed
    362. Ippoliti C, Przepiorka D, Mehra R, Neumann J, Wood J, Claxton D, Gajewski J, Khouri I, van Besien K, Andersson B, et al. Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology. 1995 Dec; 46(6):811-5. PMID: 7502421.
      View in: PubMed
    363. Pettaway CA, Pisters LL, Dinney CP, Jularbal F, Swanson DA, von Eschenbach AC, Ayala A. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 1995 Dec; 154(6):1999-2003. PMID: 7500444.
      View in: PubMed
    364. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol. 1995 Dec; 154(6):2059-63; discussion 2063-4. PMID: 7500458.
      View in: PubMed
    365. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, Xie B, Fan D, Bucana CD, Fidler IJ, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol. 1995 Oct; 154(4):1532-8. PMID: 7658585.
      View in: PubMed
    366. Dinney CP, Tanguay S, Bucana CD, Eve BY, Fidler IJ. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. J Interferon Cytokine Res. 1995 Jun; 15(6):585-92. PMID: 7553228.
      View in: PubMed
    367. Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):331-40. PMID: 7751174.
      View in: PubMed
    368. Fornage BD, Dinney CP, Troncoso P. Ultrasound-guided transperineal needle biopsy of the prostate after abdominoperineal resection. J Clin Ultrasound. 1995 May; 23(4):263-5. PMID: 7797666.
      View in: PubMed
    369. Dinney CP, Ramirez EI, Swanson DA, Ro JY, Babaian RJ, von Eschenbach AC. Management of transitional cell carcinoma involving von Brunn's nests. J Urol. 1995 Mar; 153(3 Pt 2):944-9. PMID: 7853580.
      View in: PubMed
    370. Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer. 1994 Nov 15; 74(10):2819-27. PMID: 7954243.
      View in: PubMed
    371. Amin MB, Ro JY, Lee KM, Ordóñez NG, Dinney CP, Gulley ML, Ayala AG. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol. 1994 May; 18(5):466-73. PMID: 8172321.
      View in: PubMed
    372. Dinney CP, Johnson DE, Swanson DA, Babaian RJ, von Eschenbach AC. Therapy and prognosis for male anterior urethral carcinoma: an update. Urology. 1994 Apr; 43(4):506-14. PMID: 8154072.
      View in: PubMed
    373. Babaian RJ, Dinney CP, Ramirez EI, Evans RB. Diagnostic testing for prostate cancer detection: less is best. Urology. 1993 May; 41(5):421-5. PMID: 7683834.
      View in: PubMed
    374. Dinney CP, Ro JY, Babaian RJ, Johnson DE. Lymphoepithelioma of the bladder: a clinicopathological study of 3 cases. J Urol. 1993 Apr; 149(4):840-1. PMID: 8455255.
      View in: PubMed
    375. Gohji K, Nakajima M, Dinney C, Fan D, Pathak S, Killion J, Voneschenbach A, Fidler I. The importance of orthotopic implantation to the isolation and biological characterization of a metastatic human clear cell renal-carcinoma in nude-mice. Int J Oncol. 1993 Jan; 2(1):23-32. PMID: 21573511.
      View in: PubMed
    376. Stephenson RA, Dinney CP, Gohji K, Ordóñez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst. 1992 Jun 17; 84(12):951-7. PMID: 1378502.
      View in: PubMed
    377. Dinney CP, Utsugi T, Fidler IJ, von Eschenbach AC, Killion JJ. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon. Cancer Res. 1992 Mar 01; 52(5):1155-61. PMID: 1531322.
      View in: PubMed
    378. Dinney CP, Awad SA, Gajewski JB, Belitsky P, Lannon SG, Mack FG, Millard OH. Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma. Urology. 1992 Feb; 39(2):122-9. PMID: 1736503.
      View in: PubMed
    379. Utsugi T, Dinney CP, Killion JJ, Brown D, Fidler IJ. In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells. Lymphokine Cytokine Res. 1991 Dec; 10(6):487-93. PMID: 1804312.
      View in: PubMed
    380. Dinney CP, Bucana CD, Utsugi T, Fidler IJ, von Eschenbach AC, Killion JJ. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362. Cancer Res. 1991 Jul 15; 51(14):3741-7. PMID: 1905975.
      View in: PubMed
    381. Utsugi T, Dinney CP, Killion JJ, Fidler IJ. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Cancer Immunol Immunother. 1991; 33(6):375-81. PMID: 1878891.
      View in: PubMed
    382. Dinney CP, Norman RW. Contralateral pleural effusion secondary to nonmetastatic renal cell carcinoma. J Urol. 1990 May; 143(5):1002-3. PMID: 2329586.
      View in: PubMed
    383. Oncologic Equivalence between Laparoscopic/Robotic and Open Radical Cystectomy. Journal of Urology. 195:1646-1647.
    384. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU International.
    385. Interleukin-8 expression regulates angiogenesis, tumorigenicity and metastasis in human bladder cancer. Nishinihon Journal of Urology. 63:119-127.
    386. Uncommon Cancers of the Bladder. 23-33.
    387. Erratum. European Urology. 68:171.
    388. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU International.
    389. Bladder cancer. 143-152.
    390. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Translational Andrology and Urology. 4:273-282.
    391. The importance of orthotopic implantation to the isolation and biological characterization of a metastatic human clear cell renal carcinoma in nude mice. International Journal of Oncology. 2:23-32.
    392. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. European Urology Focus.
    393. Inhibition of angiogenesis by interferon-alpha in human transitional cell carcinoma growing orthotopically in nude mice and study of combination therapy with cytoreductive chemotherapy. Nishinihon Journal of Urology. 63:223-227.
    394. Cytokine Panel for Response to Intravesical Therapy (CyPRIT). European Urology. 69:197-200.
    395. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. European Urology.
    396. Optimal treatment for androgen-dependent prostate tumors. Cancer Bulletin. 45:418-423.
    397. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer. Medicine (United States). 95.
    398. Annals of Surgical Oncology. 1-5.
    399. Erratum. Nature Genetics. 41:1156.
    400. Erratum. Nature Clinical Practice Urology. 3:623.
    401. Erratum to. World Journal of Urology. 30:723.
    402. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Journal of Urology. 186:453.
    403. Inhibition of angiogenesis and metastasis by blockade of epidermal growth factor receptor. Nishinihon Journal of Urology. 63:113-118.
    404. Annals of Surgical Oncology.
    405. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy. Urologic Oncology: Seminars and Original Investigations. 34:59.e1-59.e8.
    406. Do lymphocytes contain chromosomal lesions that are also stable markers in cancer cells? Lymphocyte and tumor cell karyotyping in a melanoma patient. International Journal of Oncology. 11:681-684.
    407. Mitochondrial DNA content as risk factor for bladder cancer and its association with mitochondrial DNA polymorphisms. Cancer Prevention Research. 8:607-613.
    408. Partial cystectomy for muscle-invasive transitional and squamous carcinoma of the bladder-is it safe?. British Journal of Urology. 80:50.
    409. Boosted C5 trees i-Biomarkers panel for invasive bladder cancer progression prediction. 190-200.
    410. Bladder cancer. 584-590.
    411. Pubourethral sling simultaneous with radical retropubic prostatectomy for patients at high risk for postprostatectomy incontinence. Prostate Cancer and Prostatic Diseases. 3.
    412. Accuracy of computed tomography for identifying locally advanced disease in patients with muscle-invasive bladder cancer. UroToday International Journal. 6.
    413. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy. European Urology.
    414. Cancer and Metastasis Reviews. Cancer and Metastasis Reviews. 28:267.
    415. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget. 7:80164-80174.
    416. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations. 34:469-476.
    417. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy. European Urology.
    418. Origins of Bladder Cancer. Annual Review of Pathology. 11:149-174.
    419. Uncommon Cancers of the Bladder. 18-26.
    420. Novel approach to interferon-alpha gene therapy for bladder cancer in a mouse model. Cancer Biology and Therapy. 3:923-924.
    421. A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Nature Clinical Practice Urology. 3:472-473.
    422. Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. Hematology/Oncology Clinics of North America. 29:377-394.
    423. Erratum. Nature Genetics. 41:1156.
    424. Intelligent clinical decision support systems for non-invasive bladder cancer diagnosis. 253-262.
    425. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World Journal of Urology.
    426. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of european ancestry. Human Molecular Genetics. 25:1203-1214.
    427. Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget. 6:4097-4109.
    428. Preface. Cancer and Metastasis Reviews. 28:267.
    429. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 12:105-117.
    430. Urachal carcinoma. Human Pathology. 46:1808-1814.
    DINNEY's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description